Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD). 

Biotechnology

Vanqua Bio

Jim Sullivan

Jesse Cedarbaum

Omer Siddiqui

Daniel Ysselstein

Jack Beyer

Kevin Hunt

The Research and Development Team at Vanqua Bio focuses on pioneering innovative therapies for neurodegenerative diseases by harnessing human genetic insights. Collaborating closely, team members design and execute experiments using proprietary research tools and patient-derived neuronal models to identify and validate drug targets, ultimately working towards groundbreaking solutions to slow or halt the progression of conditions such as Parkinson’s, Alzheimer’s, and ALS.

Research and Development Team

Research and Development

Leadership Team

Research and Development Team

About

Team members

Other teams at Vanqua Bio

Research and Development

Leadership Team